-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The newly identified antibody was isolated from the lymphocytes of COVID-19 patients who participated in the immunization coronavirus research conducted by CHUV's Immunization and Allergy Service Center
In addition to its antiviral properties, this new antibody is also designed to have a lasting effect on humans
Currently, CHUV and EPFL plan to cooperate with a start-up company to carry out clinical development and production of this antibody-containing drug through cooperation and intellectual property agreements
Treatment or prophylaxy
This research was conducted by CHUV's immunology and allergy services led by Professors Giuseppe Pantaleo and Craig Fenwick, and EPFL's Virology and Genetics Laboratory led by Professor Didier Trono and Dr.
The discovery of this new antibody marks an important step forward in the fight against COVID-19
references
Craig Fenwick, Priscilla Turelli, Laurent Perez, Céline Pellaton, Line Esteves-Leuenberger, Alex Farina, Jérémy Campos, Erica Lana, Flurin Fiscalini, Charlène Raclot, Florence Pojer, Kelvin Lau, Davide Demurtas, Marc Descatoire, Victor S.
https://doi.
Magazine
Cell report
DOI
10.
Methodological research
Experimental Study
Subject of research
animal
Article title
A highly effective antibody against SARS-CoV-2 mutation
Article publication date
12-October-2021
